Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. Ding L, et al. Among authors: matulonis ua. Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. Cell Rep. 2018. PMID: 30540933 Free PMC article.
New advances in ovarian cancer.
Liu J, Matulonis UA. Liu J, et al. Among authors: matulonis ua. Oncology (Williston Park). 2010 Jul;24(8):721-8. Oncology (Williston Park). 2010. PMID: 20718251 Free article. Review.
Bevacizumab rechallenge after first line maintenance bevacizumab.
Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Konstantinopoulos PA, et al. Among authors: matulonis ua. Gynecol Oncol. 2012 May;125(2):510-1. doi: 10.1016/j.ygyno.2012.02.013. Epub 2012 Feb 21. Gynecol Oncol. 2012. PMID: 22366591 Clinical Trial. No abstract available.
329 results